Breaking News

Financial Report: Alexion

February 3, 2016

Strensiq launched in the quarter, Soliris sales up 15%


4Q Revenues: $701 million (-17%)
4Q Earnings: $66.6 million (-57%)
FY Revenues: $2.6 billion (+21%)
FY Earnings: $144.4 million (earnings were $657 million FY14)
Comments: Soliris sales were $689 million in the quarter, up 15%. For the year, Soliris sales were $2.6 billion, up 21%. Strensiq sales were $11.6 million in the quarter and $12 million for the year. Strensiq was approved by the FDA for the treatment of perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP) in 4Q15. R&D expenses were $191 million, up 48%.
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus